Platinum Chemotherapy Induces 2,200 Mutations per Liver Sample in Childhood Hepatoblastoma Survivors

Researchers sequenced healthy and tumor liver tissue plus blood from children who received cisplatin or cisplatin-plus-carboplatin before resection, comparing results to untreated controls and fetal liver. Mutation counts scaled with cumulative platinum dose; dual-agent exposure produced higher loads than cisplatin alone. Liver cells accumulated far more mutations than blood, suggesting tissue-specific metabolism or repair differences. The pattern implicates platinum in accelerating somatic aging of hepatocytes and elevating risk for later metabolic dysfunction or secondary malignancy.

Prior Childhood Cancer Survivor Study data already link platinum exposure to increased hepatic late effects, yet lacked direct mutational evidence. The new sequencing results supply a mechanistic bridge between acute treatment and decades-later pathology, indicating that observed clinical signals may understate risk because current follow-up rarely extends past the third decade. Vasudevan and Parsons note the need for survivorship protocols that track liver outcomes into middle age.

Next steps require prospective cohorts with serial imaging and biopsy to test whether mutation burden predicts fibrosis or HCC incidence above 10 percent by age 40. Parallel work should explore whether dose de-escalation or platinum-sparing regimens can preserve efficacy while reducing mutational load.